JPH11507330A - オキサゾリジノン誘導体、その製造及び治療的使用 - Google Patents
オキサゾリジノン誘導体、その製造及び治療的使用Info
- Publication number
- JPH11507330A JPH11507330A JP8536245A JP53624596A JPH11507330A JP H11507330 A JPH11507330 A JP H11507330A JP 8536245 A JP8536245 A JP 8536245A JP 53624596 A JP53624596 A JP 53624596A JP H11507330 A JPH11507330 A JP H11507330A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- hydrogen atom
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title claims description 26
- 230000001225 therapeutic effect Effects 0.000 title abstract description 5
- -1 methylenedioxy group Chemical group 0.000 claims abstract description 133
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 67
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 24
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 18
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 18
- 125000005843 halogen group Chemical group 0.000 claims abstract description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 15
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 93
- 239000000203 mixture Substances 0.000 claims description 79
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 40
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 4
- DNSGQMOSYDHNHO-UHFFFAOYSA-N 4-(methoxymethyl)-1,3-dioxolan-2-one Chemical compound COCC1COC(=O)O1 DNSGQMOSYDHNHO-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 3
- 239000002841 Lewis acid Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000006264 debenzylation reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 150000007517 lewis acids Chemical class 0.000 claims description 3
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 241001553014 Myrsine salicina Species 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- PLTALYMSSXETDZ-UHFFFAOYSA-N 4-(phenylmethoxymethyl)-1,3-dioxolan-2-one Chemical compound O1C(=O)OCC1COCC1=CC=CC=C1 PLTALYMSSXETDZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- POXSDSRWVJZWCN-UHFFFAOYSA-N triphenylphosphanium;iodide Chemical compound I.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 POXSDSRWVJZWCN-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 18
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical group C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 abstract description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract description 3
- 125000004429 atom Chemical group 0.000 abstract description 3
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
- JSWCRCKGZPRDKQ-UHFFFAOYSA-N 5-(hydroxymethyl)-5h-1,3-oxazol-2-one Chemical class OCC1OC(=O)N=C1 JSWCRCKGZPRDKQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 238000002844 melting Methods 0.000 description 28
- 230000008018 melting Effects 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- FNDBNJUWRRLOHU-UHFFFAOYSA-N 2-fluoro-4-phenylmethoxybenzonitrile Chemical class C1=C(C#N)C(F)=CC(OCC=2C=CC=CC=2)=C1 FNDBNJUWRRLOHU-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- LSYOFPBORRARMF-UHFFFAOYSA-N 5-(hydroxymethyl)-1,3-oxazolidin-2-one Chemical class OCC1CNC(=O)O1 LSYOFPBORRARMF-UHFFFAOYSA-N 0.000 description 4
- 102000010909 Monoamine Oxidase Human genes 0.000 description 4
- 108010062431 Monoamine oxidase Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 125000000904 isoindolyl group Chemical class C=1(NC=C2C=CC=CC12)* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- PSJBSUHYCGQTHZ-BYPYZUCNSA-N (2s)-3-methoxypropane-1,2-diol Chemical compound COC[C@@H](O)CO PSJBSUHYCGQTHZ-BYPYZUCNSA-N 0.000 description 2
- FGATZKMMLFZPMC-MRVPVSSYSA-N (5R)-3-(6-hydroxy-1,2-benzoxazol-3-yl)-5-(methoxymethyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](COC)CN1C1=NOC2=CC(O)=CC=C12 FGATZKMMLFZPMC-MRVPVSSYSA-N 0.000 description 2
- ALXDBDKUDRBYJW-HNNXBMFYSA-N (5s)-5-(methoxymethyl)-3-(6-phenylmethoxy-1,2-benzothiazol-3-yl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NSC2=CC(OCC=3C=CC=CC=3)=CC=C12 ALXDBDKUDRBYJW-HNNXBMFYSA-N 0.000 description 2
- DRULDXHUZDNVAN-HNNXBMFYSA-N (5s)-5-(methoxymethyl)-3-(6-phenylmethoxy-1,2-benzoxazol-3-yl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NOC2=CC(OCC=3C=CC=CC=3)=CC=C12 DRULDXHUZDNVAN-HNNXBMFYSA-N 0.000 description 2
- SQMNCLANJWZZOG-NSHDSACASA-N (5s)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzoxazol-3-yl]-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NOC2=CC(OCCCC(F)(F)F)=CC=C12 SQMNCLANJWZZOG-NSHDSACASA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 2
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910052776 Thorium Inorganic materials 0.000 description 2
- PXAJQJMDEXJWFB-UHFFFAOYSA-N acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 125000001145 hydrido group Chemical group *[H] 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- DNSGQMOSYDHNHO-SCSAIBSYSA-N (4r)-4-(methoxymethyl)-1,3-dioxolan-2-one Chemical compound COC[C@@H]1COC(=O)O1 DNSGQMOSYDHNHO-SCSAIBSYSA-N 0.000 description 1
- ATRLVVVJFBQMEX-ZCFIWIBFSA-N (4r)-4-(methoxymethyl)-2,2-dimethyl-1,3-dioxolane Chemical compound COC[C@@H]1COC(C)(C)O1 ATRLVVVJFBQMEX-ZCFIWIBFSA-N 0.000 description 1
- FKXMKWWWEXEOFI-QMMMGPOBSA-N (5S)-3-(6-hydroxy-1,2-benzothiazol-3-yl)-5-(methoxymethyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NSC2=CC(O)=CC=C12 FKXMKWWWEXEOFI-QMMMGPOBSA-N 0.000 description 1
- FGATZKMMLFZPMC-QMMMGPOBSA-N (5S)-3-(6-hydroxy-1,2-benzoxazol-3-yl)-5-(methoxymethyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NOC2=CC(O)=CC=C12 FGATZKMMLFZPMC-QMMMGPOBSA-N 0.000 description 1
- DRULDXHUZDNVAN-OAHLLOKOSA-N (5r)-5-(methoxymethyl)-3-(6-phenylmethoxy-1,2-benzoxazol-3-yl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](COC)CN1C1=NOC2=CC(OCC=3C=CC=CC=3)=CC=C12 DRULDXHUZDNVAN-OAHLLOKOSA-N 0.000 description 1
- IOGPJCPJAQQLFL-OIUHTZQUSA-N (5r)-5-(methoxymethyl)-3-[6-[(e,4r)-5,5,5-trifluoro-4-hydroxypent-1-enyl]-1,2-benzoxazol-3-yl]-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](COC)CN1C1=NOC2=CC(\C=C\C[C@@H](O)C(F)(F)F)=CC=C12 IOGPJCPJAQQLFL-OIUHTZQUSA-N 0.000 description 1
- QXMCTTHQHAWMSC-LBPRGKRZSA-N (5s)-5-(methoxymethyl)-3-[1-methyl-6-(4,4,4-trifluorobutoxy)indazol-3-yl]-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NN(C)C2=CC(OCCCC(F)(F)F)=CC=C12 QXMCTTHQHAWMSC-LBPRGKRZSA-N 0.000 description 1
- ZWTMSEROLHBUQZ-NSHDSACASA-N (5s)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzothiazol-3-yl]-1,3-oxazolidin-2-one Chemical compound O=C1O[C@H](COC)CN1C1=NSC2=CC(OCCCC(F)(F)F)=CC=C12 ZWTMSEROLHBUQZ-NSHDSACASA-N 0.000 description 1
- GYOHTBTWJCEDCN-UHFFFAOYSA-N (6-phenylmethoxy-1,2-benzothiazol-3-yl) carbamate Chemical compound C(N)(OC1=NSC2=C1C=CC(=C2)OCC1=CC=CC=C1)=O GYOHTBTWJCEDCN-UHFFFAOYSA-N 0.000 description 1
- LDRPULCXZDDSGE-UHFFFAOYSA-N 1,1,1-trifluorobutane Chemical compound CCCC(F)(F)F LDRPULCXZDDSGE-UHFFFAOYSA-N 0.000 description 1
- RQXXCWHCUOJQGR-UHFFFAOYSA-N 1,1-dichlorohexane Chemical compound CCCCCC(Cl)Cl RQXXCWHCUOJQGR-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-PPJXEINESA-N 2-((114C)cyclohexatrienyl)ethanamine Chemical compound NCC[14C]1=CC=CC=C1 BHHGXPLMPWCGHP-PPJXEINESA-N 0.000 description 1
- REIVHYDACHXPNH-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C(F)=C1 REIVHYDACHXPNH-UHFFFAOYSA-N 0.000 description 1
- UIDGLNLWRJTUEN-UHFFFAOYSA-N 3-(1H-pyrrol-3-yl)-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1C1=CNC=C1 UIDGLNLWRJTUEN-UHFFFAOYSA-N 0.000 description 1
- XBBGKWGBCSKLJY-UHFFFAOYSA-N 3-(6-ethenyl-1,2-benzoxazol-3-yl)-4-(methoxymethyl)-1,3-oxazolidin-2-one Chemical compound COCC1COC(=O)N1c1noc2cc(C=C)ccc12 XBBGKWGBCSKLJY-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- TWZDUIPNCURWOU-UHFFFAOYSA-N 4-phenylmethoxy-2-(propan-2-ylideneamino)oxybenzonitrile Chemical compound C1=C(C#N)C(ON=C(C)C)=CC(OCC=2C=CC=CC=2)=C1 TWZDUIPNCURWOU-UHFFFAOYSA-N 0.000 description 1
- VUJMLRJWXXZRGU-UHFFFAOYSA-N 6-phenylmethoxy-1,2-benzoxazol-3-amine Chemical compound C=1C=C2C(N)=NOC2=CC=1OCC1=CC=CC=C1 VUJMLRJWXXZRGU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- XOWOUARHTZFEQH-NSHDSACASA-N C1[C@H](OC(=O)N1C2=NOC3=C2C=CC(=C3)OCCCC(F)(F)F)O Chemical compound C1[C@H](OC(=O)N1C2=NOC3=C2C=CC(=C3)OCCCC(F)(F)F)O XOWOUARHTZFEQH-NSHDSACASA-N 0.000 description 1
- KCJPLWAFCYCREA-SNVBAGLBSA-N CCC1=CC2=C(C=C1)C(=NO2)N3C[C@@H](OC3=O)COC Chemical compound CCC1=CC2=C(C=C1)C(=NO2)N3C[C@@H](OC3=O)COC KCJPLWAFCYCREA-SNVBAGLBSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- WGPAQYSVWYWZKT-UHFFFAOYSA-N [C].[Ra] Chemical compound [C].[Ra] WGPAQYSVWYWZKT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- GJQBHOAJJGIPRH-UHFFFAOYSA-N benzoyl cyanide Chemical compound N#CC(=O)C1=CC=CC=C1 GJQBHOAJJGIPRH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- BDUPRNVPXOHWIL-UHFFFAOYSA-N dimethyl sulfite Chemical compound COS(=O)OC BDUPRNVPXOHWIL-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- FODMYKBPPMSXTQ-UHFFFAOYSA-N n,n-dimethylformamide;oxolan-2-one Chemical compound CN(C)C=O.O=C1CCCO1 FODMYKBPPMSXTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- GCWKZDAYUIQXLD-ZMBIFBSDSA-M triphenyl-[(3r)-4,4,4-trifluoro-3-hydroxybutyl]phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC[C@@H](O)C(F)(F)F)C1=CC=CC=C1 GCWKZDAYUIQXLD-ZMBIFBSDSA-M 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一般式(I): [式中、Xは酸素原子、硫黄原子又は基NR(Rは水素原子又は直鎖若しくは分 岐鎖のC1−C4アルキル鎖である)を表し、 R1は、水素原子又はメチル基を表し、そして R2は、 (i)基R3O(R3は、水素原子、又は場合によりハロゲン原子若しくはニトロ 若しくはメチレンジオキシ基で置換されているベンジル基を表すか、又はメトキ シエチル、ブチル、4,4,4−トリフルオロブチル、4,4,4−トリフルオロ− 3−ヒドロキシブチル又は4,4,4−トリフルオロブタ−2−エニル基を表す) 、又は (ii)基−CH=CH−R4又は−CH2−CH2−R4(R4は、水素原子、又 はフェニル、3,3,3−トリフルオロプロピル又は3,3,3−トリフルオロ−2 −ヒドロキシプロピル基を表す) を表す] で示される、エナンチオマー又はジアステレオマーの形態、又はラセミ混合物を 含むこれら様々な形態の混合物である、5−(ヒドロキシメチル)オキサゾリジ ン−2−オン誘導体。 2.一般式(I) [式中、Xが酸素原子、硫黄原子又は基NR(Rは水素原子又は直鎖若しくは分 岐鎖のC1−C4アルキル鎖である)を表し、 R1がメチル基又は水素原子を表し、そして R2が基R3O(式中R3は、水素原子、又は場合によりハロゲン原子若しくは ニトロ若しくはメチレンジオキシ基で置換されているベンジル基を表すか、又は メトキシエチル、ブチル、4,4,4−トリフルオロブチル、4,4,4−トリフル オロ−3−ヒドロキシブチル又は4,4,4−トリフルオロブタ−2−エニル基を 表す)を表す] で示される、エナンチオマー又はジアステレオマーの形態、又はラセミ混合物を 含むこれら様々な形態の混合物である、5−(ヒドロキシメチル)オキサゾリジ ン−2−オン誘導体。 3.一般式(I) [式中、Xが酸素原子、硫黄原子又は基NR(Rは水素原子又は直鎖若しくは分 岐鎖のC1−C4アルキル鎖である)を表し、 R1がメチル基又は水素原子を表し、そして R2が基−CH=CH−R4又は−CH2−CH2−R4(R4は、水素原子、又は フェニル、3,3,3−トリフルオロプロピル又は3,3,3−トリフルオロ−2− ヒドロキシプロピル基を表す)を表す] で示される、エナンチオマー又はジアステレオマーの形態、又はラセミ混合物を 含むこれら種々の形態の混合物である、5−(ヒドロキシメチル)オキサゾリジ ン−2−オン誘導体。 4.一般式(I) [式中、Xは酸素原子を表し、 R1は、メチル基又は水素原子を表し、そして R2は、 (i)基R3O(R3は、水素原子、又は場合によりハロゲン原子若しくはニトロ 若しくはメチレンジオキシ基で置換されているベンジル基を表すか、又はメトキ シエチル、ブチル、4,4,4−トリフルオロブチル、4,4,4−トリフルオロ− 3−ヒドロキシブチル又は4,4,4−トリフルオロブタ−2−エニル基を表す) 、 又は (ii)基−CH=CH−R4又は−CH2−CH2−R4(R4は、水素原子、又 はフェニル、3,3,3−トリフルオロプロピル又は3,3,3−トリフルオロ−2 −ヒドロキシプロピル基を表す)を表す] で示される、エナンチオマー又はジアステレオマーの形態、又はラセミ混合物を 含むこれら様々な形態の混合物である、5−(ヒドロキシメチル)オキサゾリジ ン−2−オン誘導体。 5.一般式(I) [式中、Xは酸素原子を表し、 R1は、メチル基又は水素原子を表し、そして R2は、ヒドロキシル基、又は場合によりハロゲン原子若しくはニトロ若しく はメチレンジオキシ基で置換されているフェニルメトキシ基のいずれかを表すか 、又は4,4,4−トリフルオロブトキシ基、又は4,4,4−トリフルオロ−3− ヒドロキシブトキシ基を表す] で示される、エナンチオマー又はジアステレオマーの形態、又はラセミ混合物を 含むこれら様々な形態の混合物である、5−(ヒドロキシメチル)オキサゾリジ ン−2−オン誘導体。 6.(S)−5−メトキシメチル−3−[6−(4,4,4−トリフルオロブトキ シ)−1,2−ベンズイソキサゾール−3−イル]オキサゾリジン−2−オン。 7.式(I) [式中、Xは酸素原子、硫黄原子又は基NR(Rは水素原子又は直鎖若しくは分 岐鎖のC1−C4アルキル鎖である)を表し、 R1は、メチル基を表し、 R2は、基R3O(R3は、水素原子、又は場合によりハロゲン原子若しくはニ トロ若しくはメチレンジオキシ基で置換されているベンジル基を表すか、又はメ トキシエチル、ブチル、4,4,4−トリフルオロブチル、4,4,4−トリフルオ ロ−3−ヒドロキシブチル又は4,4,4−トリフルオロブタ−2−エニル基を表 す)を表す] で示される化合物の製造方法であって、式(II): で示される化合物を、式(IIIa): で示される4−メトキシメチル−1,3−ジオキソラン−2オンの4(R)又は 4(S)異性体のいずれか一方により、炭酸カリウムの存在下で処理し、式(I a): で示される化合物の5(S)又は5(R)異性体を得、これを接触水素化による か又はLewis酸の助けをかりて脱ベンジル化して、式((Ib)R1=CH3): で示される化合物の5(S)又は5(R)異性体を得、これを式R3Y[R3は、 水素と置換されていないベンジルとでないこと以外は式(I)と同意義であり、 Yは、塩素又は臭素原子又はトシルオキシ基のような脱離基である]で示される 化合物により、炭酸カリウムの存在下で処理するか、 又は式R3OH[R3は前記と同意義である]で示される化合物によりトリフェニ ルホスフィン及びジエチルアゾジカルボキシレートの存在下に処理して、式(( Ic)、R1=CH3: で示される化合物の5(S)又は5(R)異性体を得、必要ならばX=NCH3 である化合物をベンゾイルペルオキシドで処理して、X=NH基である式(Ih ) で示される化合物を得ることを特徴とする方法。 8.式(I)[式中、R1は水素原子を表し、置換基X及びR2は前記と同意義で ある]で示される化合物の製造方法であって、式(II) で示されるエチル6−フェニルメトキシ−1,2−ベンズイソキサゾール−3− カルバメートを、式(IIIb) で示される4−フェニルメトキシメチル−1,3−ジオキソラン−2−オンの4 (S)又は4(R)異性体のいずれか一方により、炭酸カリウムの存在下で処理 して、式(VI): で示される化合物の5(R)又は5(S)異性体を得、これを接触水素化により 脱ベンジル化して式((Ib)、R1=H) で示される化合物の5(R)又は5(S)異性体を得、次いでこれを式R3Y[ R3は、水素でないこと以外は式(I)と同意義であり、Yは、塩素若しくは臭 素原子又はトシルオキシ基のような脱離基である]で示される化合物により、炭 酸カリウムの存在下で処理して、式((Ic)、R1=H) で示される化合物の5(R)又は5(S)異性体を得ることを特徴とする方法。 9.式(I)[式中、Xは酸素原子、硫黄原子又は基NR(Rは水素原子又は直 鎖若しくは分岐鎖のC1−C4アルキル鎖である)を表し、そして R1は、水素原子又はメチル基を表し、 R2は、基−CH=CH−R4又は−CH2−CH2−R4(R4は、水素原子、又 はフェニル、3,3,3−トリフルオロプロピル又は3,3,3−トリフルオロ−2 −ヒドロキシプロピル基を表す)を表す] で示される化合物の製造方法であって、式((Ib)、R1=CH3) で示される化合物をトリフルオロメタンスルホン酸無水物で処理すること、 得られた式(IV) で示される化合物を、塩化リチウム及びテトラキス(トリフェニルホスフィン) パラジウムの存在下にトリブチルビニル錫と反応させること、 式(Id) で示される化合物を、オゾン、次いでジメチルスルフィドで処理すること、 式(V) で示される化合物を、式R4CH2PPh3 +I-[R4は水素でないこと以外は、式 (I)と同意義である]で示されるトリフェニルホスホニウムヨージドと、炭酸 カリウムの存在下に反応させること、 式(Ie) で示される化合物を、水素により、触媒の存在下に還元して、式(If) [式中、R4は前記と同意義である] で示される化合物を得ること、そして 最後に、この化合物を三臭化ホウ素で処理して、式(Ig) で示される化合物を得ることを含むことを特徴とする方法。 10.請求項1に記載の式(I)で示される化合物からなることを特徴とする薬 物。 11.請求項1に記載の式(I)で示される化合物を、いずれかの適当な添加剤 と組み合わせて含んでなることを特徴とする医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9506564A FR2734821B1 (fr) | 1995-06-02 | 1995-06-02 | Derives de 5-methoxymethyl-3-(1,2-benzisoxazol-3-yl) oxazolidin-2-one, leur preparation et leur application en therapeutique |
| FR9506563A FR2734820B1 (fr) | 1995-06-02 | 1995-06-02 | Derives de 3-(1,2-benzisoxazol-3-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique |
| FR95/06564 | 1995-06-02 | ||
| FR95/06563 | 1995-06-02 | ||
| PCT/FR1996/000792 WO1996038444A1 (fr) | 1995-06-02 | 1996-05-28 | Derives d'oxazolidinone, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11507330A true JPH11507330A (ja) | 1999-06-29 |
| JP3856829B2 JP3856829B2 (ja) | 2006-12-13 |
Family
ID=26232004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53624596A Expired - Lifetime JP3856829B2 (ja) | 1995-06-02 | 1996-05-28 | オキサゾリジノン誘導体、その製造及び治療的使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5843975A (ja) |
| EP (1) | EP0835254B1 (ja) |
| JP (1) | JP3856829B2 (ja) |
| KR (1) | KR100457502B1 (ja) |
| CN (1) | CN1075072C (ja) |
| AR (1) | AR006301A1 (ja) |
| AT (1) | ATE184005T1 (ja) |
| AU (1) | AU699367B2 (ja) |
| BR (1) | BR9608896A (ja) |
| CA (1) | CA2223011C (ja) |
| CO (1) | CO4700462A1 (ja) |
| CZ (1) | CZ378497A3 (ja) |
| DE (1) | DE69604071T2 (ja) |
| DK (1) | DK0835254T3 (ja) |
| ES (1) | ES2138346T3 (ja) |
| GR (1) | GR3031710T3 (ja) |
| HU (1) | HU224879B1 (ja) |
| MX (1) | MX9709410A (ja) |
| NO (1) | NO309091B1 (ja) |
| NZ (1) | NZ310487A (ja) |
| PL (1) | PL183919B1 (ja) |
| RU (1) | RU2164226C2 (ja) |
| SK (1) | SK281934B6 (ja) |
| TW (1) | TW360654B (ja) |
| WO (1) | WO1996038444A1 (ja) |
| ZA (1) | ZA964563B (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008120655A1 (ja) * | 2007-03-30 | 2008-10-09 | Institute Of Medicinal Molecular Design, Inc. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体 |
| JP2009173657A (ja) * | 2001-01-31 | 2009-08-06 | H Lundbeck As | うつ病および/又は不安症を治療するためのgal3受容体アンタゴニストの使用、およびこのような方法において有用な化合物 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1078632A1 (en) * | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| CZ2004359A3 (cs) * | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty |
| DE10334309A1 (de) * | 2003-07-28 | 2005-03-03 | Aventis Pharma Deutschland Gmbh | Substituierte Thiazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| WO2007088438A2 (en) * | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Benzisoxazole oxazolidinones as antibacterial agents |
| EP2123159A1 (de) * | 2008-05-21 | 2009-11-25 | Bayer CropScience AG | (1,2-Benzisothiazol-3-yl)(thio)carbamate und (1,2-Benzisothiazol-3-yl)(thio)oxamate und deren Oxidationsformen als Pestizide |
| AU2010330894A1 (en) * | 2009-12-18 | 2012-07-05 | Janssen Pharmaceutica Nv | Substituted aminothiazolone indazoles as estrogen related receptor-aalpha modulators |
| JP2013519729A (ja) * | 2010-02-17 | 2013-05-30 | ヤンセン ファーマシューティカ エヌ.ベー. | エストロゲン関連受容体α変調剤としてのアミノチアゾロン |
| WO2016097355A1 (en) * | 2014-12-19 | 2016-06-23 | Ge Healthcare Limited | Labelled oxazolidinone derivatives |
| DE102015012050A1 (de) * | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| RU2637643C1 (ru) * | 2016-09-05 | 2017-12-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) | Иммунодепрессант |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2076253T3 (es) * | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
| FR2653017B1 (fr) * | 1989-10-17 | 1995-05-05 | Delalande Sa | Derives d'aryl-3 oxazolidinone-2, leur procede de preparation et leur application en therapeutique. |
| US5196543A (en) * | 1989-10-17 | 1993-03-23 | Delalande S.A. | 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy |
| US5235063A (en) * | 1989-10-17 | 1993-08-10 | Delalande S.A. | Process of preparing by condensation certain |
| US5182296A (en) * | 1989-10-26 | 1993-01-26 | Tanabe Seiyaky Co., Ltd. | Naphthyloxazolidone derivatives |
| FR2671350A1 (fr) * | 1991-01-08 | 1992-07-10 | Adir | Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant. |
| EP0525209A4 (en) * | 1991-02-20 | 1993-06-30 | Yusaku Koda | Articulator |
-
1996
- 1996-05-28 AT AT96918719T patent/ATE184005T1/de active
- 1996-05-28 DK DK96918719T patent/DK0835254T3/da active
- 1996-05-28 DE DE69604071T patent/DE69604071T2/de not_active Expired - Lifetime
- 1996-05-28 CA CA002223011A patent/CA2223011C/en not_active Expired - Lifetime
- 1996-05-28 AU AU61288/96A patent/AU699367B2/en not_active Expired
- 1996-05-28 RU RU98100257/04A patent/RU2164226C2/ru active
- 1996-05-28 JP JP53624596A patent/JP3856829B2/ja not_active Expired - Lifetime
- 1996-05-28 NZ NZ310487A patent/NZ310487A/xx not_active IP Right Cessation
- 1996-05-28 PL PL96323673A patent/PL183919B1/pl unknown
- 1996-05-28 EP EP96918719A patent/EP0835254B1/fr not_active Expired - Lifetime
- 1996-05-28 CZ CZ973784A patent/CZ378497A3/cs unknown
- 1996-05-28 KR KR1019970708666A patent/KR100457502B1/ko not_active Expired - Lifetime
- 1996-05-28 WO PCT/FR1996/000792 patent/WO1996038444A1/fr not_active Ceased
- 1996-05-28 ES ES96918719T patent/ES2138346T3/es not_active Expired - Lifetime
- 1996-05-28 HU HU9901349A patent/HU224879B1/hu unknown
- 1996-05-28 US US08/973,246 patent/US5843975A/en not_active Expired - Lifetime
- 1996-05-28 BR BR9608896A patent/BR9608896A/pt active IP Right Grant
- 1996-05-28 SK SK1614-97A patent/SK281934B6/sk not_active IP Right Cessation
- 1996-05-28 CN CN96195713A patent/CN1075072C/zh not_active Expired - Lifetime
- 1996-05-31 CO CO96028173A patent/CO4700462A1/es unknown
- 1996-06-01 TW TW085106564A patent/TW360654B/zh not_active IP Right Cessation
- 1996-06-03 AR ARP960102870A patent/AR006301A1/es active IP Right Grant
- 1996-06-03 ZA ZA964563A patent/ZA964563B/xx unknown
-
1997
- 1997-12-01 NO NO975530A patent/NO309091B1/no not_active IP Right Cessation
- 1997-12-02 MX MX9709410A patent/MX9709410A/es unknown
-
1999
- 1999-11-03 GR GR990402802T patent/GR3031710T3/el unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009173657A (ja) * | 2001-01-31 | 2009-08-06 | H Lundbeck As | うつ病および/又は不安症を治療するためのgal3受容体アンタゴニストの使用、およびこのような方法において有用な化合物 |
| WO2008120655A1 (ja) * | 2007-03-30 | 2008-10-09 | Institute Of Medicinal Molecular Design, Inc. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体 |
| JPWO2008120655A1 (ja) * | 2007-03-30 | 2010-07-15 | 株式会社医薬分子設計研究所 | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0433149B1 (fr) | Antagonistes de la sérotonine, leur préparation et les médicaments les contenant | |
| JPH11502221A (ja) | モルホリン誘導体、該誘導体を含有する組成物、及びこれらの治療薬としての使用 | |
| JP3856829B2 (ja) | オキサゾリジノン誘導体、その製造及び治療的使用 | |
| EP0350403B1 (fr) | Dérivés de (aza)naphtalènesultame, leurs procédés de préparation et les médicaments les contenant | |
| CA2096475A1 (fr) | Derives du benzimidazole; leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HUT70539A (en) | Benzoxazine derivatives pharmaceutical compositions containing them and process for producing them | |
| EP0841330B1 (fr) | Nouveaux dérivés aminométhyl hétérocycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| HU204517B (en) | Process for producing new 1,4-benzoxazine derivatives and pharmaceutical compositions containing them | |
| CA2000091A1 (fr) | Derives de la benzoxazolinone, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP0891358A1 (fr) | Composes derives d'oxazolidin-2-one, leur procede de preparation et leur application en therapeutique | |
| US6143772A (en) | Compounds derived from 3-(benzofuran-5-yl)oxazolidin-2-one, preparation method therefor and therapeutical use thereof | |
| EP1790646A1 (fr) | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. | |
| EP0859776A1 (fr) | Composes derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique | |
| JP4171297B2 (ja) | 4,5−ジヒドロ−チアゾ−2−イルアミン誘導体およびそれらのno合成酵素阻害剤としての使用 | |
| EP0980368B1 (fr) | Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 | |
| FR2734820A1 (fr) | Derives de 3-(1,2-benzisoxazol-3-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique | |
| FR2734821A1 (fr) | Derives de 5-methoxymethyl-3-(1,2-benzisoxazol-3-yl) oxazolidin-2-one, leur preparation et leur application en therapeutique | |
| JPH10503508A (ja) | Ii型糖尿病の治療において有用なベンゾオキサゾールおよびピリジン誘導体 | |
| WO1998050383A1 (fr) | Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4 | |
| FR2751651A1 (fr) | Derives de 3-(benzo[b]thien-3-yl)oxazolidin-2-one, leur procede de preparation et leur application en therapeutique | |
| FR2655652A1 (fr) | Antagonistes de la serotonine, leur preparation et les medicaments les contenant. | |
| FR2630113A2 (fr) | Derives de ((piperidinyl-4)methyl)-2 tetrahydro-1,2,3,4 isoquinoleine, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041229 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050712 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051004 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060112 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060713 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060822 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060913 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100922 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100922 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110922 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120922 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130922 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |